FDA Approves Xembify (immune globulin subcutaneous) for Primary Immunodeficiencies

Barcelona, July 4, 2019.- Grifols, a leading global producer of plasma-derived medicines, announced today that Xembify, its new 20% subcutaneous immunoglobulin, has been approved by the U.S. Food and Drug Administration (FDA). Xembify is used to...
Source: Drugs.com - New Drug Approvals - Category: Drugs & Pharmacology Source Type: news

Related Links:

Publication date: Available online 8 October 2020Source: The Journal of Allergy and Clinical Immunology: In PracticeAuthor(s): Hsi-en Ho, Sheryl Mathew, Michael J. Peluso, Charlotte Cunningham-Rundles
Source: The Journal of Allergy and Clinical Immunology: In Practice - Category: Allergy & Immunology Source Type: research
Epstein –Barr virus (EBV) is associated with the pathogenesis of a variety of malignancies, most notably lymphomas. Especially in the background of immunodeficiency, such as primary immunodeficiency disorder (P...
Source: Diagnostic Pathology - Category: Pathology Authors: Tags: Case Report Source Type: research
ConclusionsSubcutaneous IgPro20 manual push infusions at flow rates up to 2.0  mL/min were well tolerated and reduced infusion time in treatment-experienced patients with PID.Trial RegistrationNCT03033745
Source: Journal of Clinical Immunology - Category: Allergy & Immunology Source Type: research
Primary immunodeficiencies are a heterogeneous group of rare inborn diseases affecting different components of the immune system. [1] A subgroup of patients with severe primary T-cell deficiencies is at risk for life-threatening viral and opportunistic infections. Without the reconstitution of a functional T-cell system, the prognosis is often dismal and infections lead to death within the first years of life. The establishment of T-cell function is usually achieved by allogeneic hematopoietic stem cell transplantation (HSCT), which can be preceded by conditioning regimens of various intensity.
Source: Biology of Blood and Marrow Transplantation - Category: Hematology Authors: Tags: Brief Article Source Type: research
Authors: Zaremehrjardi F, Baniadam L, Seif F, Arshi S, Bemanian MH, Shokri S, Rezaeifar A, Fallahpour M, Nabavi M Abstract Increased susceptibility to autoimmunity, malignancy, and allergy in addition to recurrent infections are the main characteristics suggesting for the primary immunodeficiency diseases (PID). CTLA-4 is predominantly expressed on activated and regulatory T-cells, which can bind to CD80/CD86 molecules on antigen-presenting cells as a negative regulator. Here, we describe a 24-year-old male born from consanguineous parents with heterozygous CTLA-4 mutation who presented with multiple autoimmune dis...
Source: Iranian Journal of Immunology - Category: Allergy & Immunology Tags: Iran J Immunol Source Type: research
X-linked lymphoproliferative disease (XLP) is a rare inherited X-linked primary immunodeficiency diseases (PID). One such disease, X-linked inhibitor of apoptosis protein (XIAP) deficiency, is characterized by...
Source: BMC Pediatrics - Category: Pediatrics Authors: Tags: Case report Source Type: research
Condition:   Interstitial Lymphocytic Lung Disease Interventions:   Drug: Rituximab;   Drug: Abatacept Sponsor:   Federal Research Institute of Pediatric Hematology, Oncology and Immunology Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
In 2015, heterozygous mutations in NFKB1, encoding the central component of the canonical NF- κB pathway, were identified in families with an autosomal-dominant form of common variable immunodeficiency (CVID), the most common primary immunodeficiency. Subsequently, NFKB1 defects were recognized to be associated with highly variable phenotypes, ranging from severe immune dysregulation involv ing almost any organ to nearly clinically unapparent disease. In this issue of the Journal, Lorenzini et al (p 901) describe the spectrum of this rare monogenetic condition in an international cohort comprising 231 individual...
Source: Journal of Allergy and Clinical Immunology - Category: Allergy & Immunology Authors: Tags: The Editors ’ Choice Source Type: research
Conclusion: Although our study did not assess the frequency of PIDD in patients presenting with neutropenia, the possibility of a primary immune disorder should be considered in patients with idiopathic neutropenia.
Source: Journal of Pediatric Hematology Oncology - Category: Hematology Tags: Online Articles: Original Articles Source Type: research
CONCLUSION: A modified IDR score with seven additional criteria validated in adults referred to immunology with suspicion of a PID could be used clinically to aid PID diagnosis, although further validation in different patient cohorts is required before it is used in other contexts. PMID: 32990325 [PubMed - as supplied by publisher]
Source: Clinical and Developmental Immunology - Category: Allergy & Immunology Authors: Tags: Clin Exp Immunol Source Type: research
More News: Drugs & Pharmacology | Food and Drug Administration (FDA) | Gammagard Liquid | Primary Immunodeficiency Disease | Privigen